
Strikeout Pharma plans to accelerate the commercialization of 'AR1001,' an oral Alzheimer's disease treatment candidate secured from Aribio. Strikeout Pharma holds the rights to manufacture AR1001 in Korea and has exclusive sales rights. It is also the second-largest shareholder of Aribio.
On the 18th, Strikeout Pharma stated, "We judge the global Phase 3 clinical trial results for Aribio's AR1001 to be successful and will work with Aribio to accelerate commercialization."
Previously, on the 17th, Aribio announced key results from the Phase 3 clinical trial 'POLARIS-AD' of AR1001 at the Alzheimer's disease clinical trial conference 'CTAD 2026' held in Boston, USA.
POLARIS-AD is a global Phase 3 clinical trial in which 1,535 early-stage Alzheimer's disease patients across 13 countries were administered either 30mg of AR1001 or a placebo once daily for 52 weeks. In the monotherapy group (604 patients) who did not take existing treatments, AR1001 delayed deterioration in the Clinical Dementia Rating Sum of Boxes (CDR-SB), the primary endpoint, by 31% compared to placebo (-0.44 points, p=0.0266).
A significant difference of 0.7 points was also observed in the Mini-Mental State Examination (MMSE), a secondary endpoint (p=0.0232). In biomarkers, cGMP increased significantly, and p-tau217 decreased significantly compared to placebo (p=0.0402). This serves as evidence that AR1001 acted in the brain as intended.
Safety was also favorable. The incidence of serious adverse events was similar at 10.0% in the AR1001 group and 9.8% in the placebo group.
Kim Sang-jin, President of Strikeout Pharma, who attended the local presentation in Boston, said, "We judge that AR1001 has succeeded in global Phase 3 clinical trials," adding, "I received congratulations and encouragement from Professor Sharon Xie, who presented the results, and many clinicians on site." He further added, "We also agreed with the CEO of Fuxing Pharma, who attended with us, to coordinate efforts for rapid commercialization."
President Kim cited lessons from Phase 2 as the background for this achievement. He stated, "We reflected the finding that patients in the group not co-administered symptomatic treatments showed better efficacy in Phase 2 into the design stage of the Phase 3 protocol."
He continued, "During the clinical approval stages with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), we negotiated to set strict success criteria for both the overall population and the monotherapy group separately, such that achieving the primary goal would be considered if either group met the criteria." He added, "Based on this, we will expedite approval procedures and commercialization."
Meanwhile, Aribio has signed a global exclusive licensing agreement with China's Fuxing Pharma for AR1001 and is preparing for the commercialization of the new drug. In July, Fuxing Pharma agreed to invest a total of 42.5 billion won in Aribio, of which it paid the first tranche of 11.475 billion won last month. If Fuxing Pharma exercises its additional investment option, it will secure approximately 5% of Aribio's shares, becoming the third-largest shareholder after Aribio Holdings and Strikeout Pharma. As of September 30, Strikeout Pharma's shareholding ratio in Aribio was 5.91%.